在被表型鉴定为异喹胍代谢能力差或代谢能力强的健康志愿者中静脉注射昂丹司琼后的药代动力学。
The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.
作者信息
Ashforth E I, Palmer J L, Bye A, Bedding A
机构信息
Department of Clinical Pharmacokinetics, Glaxo Group Research Ltd, Greenford, Middlesex.
出版信息
Br J Clin Pharmacol. 1994 Apr;37(4):389-91. doi: 10.1111/j.1365-2125.1994.tb04294.x.
Abstract
The pharmacokinetics of the 5-HT3 receptor antagonist ondansetron following an 8 mg i.v. dose were investigated in 12 subjects previously phenotyped with debrisoquine. Six subjects were poor metabolisers (debrisoquine metabolic ratios 29-131) and six were extensive metabolisers (debrisoquine metabolic ratios 0.45-3.4). There was no significant difference in AUC, Cmax, CL or t1/2 between the poor and extensive metabolisers. It is concluded that ondansetron clearance is not mediated exclusively by cytochrome P-450 2D6.
摘要
在12名先前已用异喹胍进行表型分型的受试者中，研究了静脉注射8毫克5-羟色胺3（5-HT3）受体拮抗剂昂丹司琼后的药代动力学。6名受试者为慢代谢者（异喹胍代谢比为29 - 131），6名受试者为快代谢者（异喹胍代谢比为0.45 - 3.4）。慢代谢者和快代谢者之间的曲线下面积（AUC）、最大血药浓度（Cmax）、清除率（CL）或半衰期（t1/2）无显著差异。得出的结论是，昂丹司琼的清除并非仅由细胞色素P - 450 2D6介导。
相似文献
1
The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.在被表型鉴定为异喹胍代谢能力差或代谢能力强的健康志愿者中静脉注射昂丹司琼后的药代动力学。
Br J Clin Pharmacol. 1994 Apr;37(4):389-91. doi: 10.1111/j.1365-2125.1994.tb04294.x.
2
Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.用于确定异喹胍4-羟化（细胞色素P4502D6）表型的遗传和代谢标准。
Pharmacogenetics. 1991 Oct;1(1):33-41. doi: 10.1097/00008571-199110000-00006.
3
Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.CYP2D6而非CYP2C19参与了尼麦角林在人体内的代谢。
Br J Clin Pharmacol. 1996 Dec;42(6):707-11. doi: 10.1046/j.1365-2125.1996.00471.x.
4
Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.美芬妥英和异喹胍羟基化表型随时间的再现性。
Pharmacol Toxicol. 1993 Jul;73(1):46-8. doi: 10.1111/j.1600-0773.1993.tb01956.x.
5
Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.南太平洋波利尼西亚人群中异喹胍（CYP2D6）和氯胍（CYP2C19）的基因多态性。
Eur J Clin Pharmacol. 1998 Jul;54(5):431-5. doi: 10.1007/s002280050488.
6
Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine.马普替林的代谢似乎与由基因决定的异喹胍CYP2D6多态性羟基化共同分离。
Br J Clin Pharmacol. 1994 Apr;37(4):383-8. doi: 10.1111/j.1365-2125.1994.tb04293.x.
7
Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?司巴丁/异喹胍的代谢不良者是否比代谢正常者对疼痛的耐受性更低？
Pain. 1993 Jun;53(3):335-339. doi: 10.1016/0304-3959(93)90229-I.
8
Debrisoquine hydroxylation in a Polish population.
Eur J Clin Pharmacol. 1995;47(6):503-5. doi: 10.1007/BF00193702.
9
Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.曲马多在细胞色素P450 2D6广泛代谢者和慢代谢者中的绝对口服生物利用度。
Clin Pharmacokinet. 2006;45(10):989-1001. doi: 10.2165/00003088-200645100-00003.
10
DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.
Hum Genet. 1993 Oct;92(4):367-72. doi: 10.1007/BF01247337.
引用本文的文献
1
CYP2D6 genotype and associated 5-HT receptor antagonist outcomes: A systematic review and meta-analysis.CYP2D6基因分型与5-羟色胺受体拮抗剂相关结局：一项系统评价与荟萃分析
Clin Transl Sci. 2025 Feb;18(2):e70108. doi: 10.1111/cts.70108.
2
A Physiologically Based Pharmacokinetic Model to Predict Systemic Ondansetron Concentration in Liver Cirrhosis Patients.一种基于生理的药代动力学模型，用于预测肝硬化患者体内昂丹司琼的全身浓度。
Pharmaceuticals (Basel). 2023 Dec 6;16(12):1693. doi: 10.3390/ph16121693.
3
Associations between ondansetron and the incidence of postoperative nausea and vomiting and food intake in Japanese female undergoing laparoscopic gynecological surgery: a retrospective study.昂丹司琼与日本女性腹腔镜妇科手术后恶心呕吐和食物摄入发生率的关系：一项回顾性研究。
J Anesth. 2024 Apr;38(2):185-190. doi: 10.1007/s00540-023-03295-0. Epub 2023 Dec 18.
4
Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator.用于 Simcyp 基于人群的模拟器中 PBPK 建模的复合文件开发指南。
CPT Pharmacometrics Syst Pharmacol. 2022 Jul;11(7):805-821. doi: 10.1002/psp4.12791. Epub 2022 Apr 18.
5
PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.药物基因组学知识库总结：昂丹司琼和托烷司琼的作用途径、药代动力学和药效学。
Pharmacogenet Genomics. 2019 Jun;29(4):91-97. doi: 10.1097/FPC.0000000000000369.
6
A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.用于预测经多种酶途径代谢的药物在孕妇体内药代动力学的基于生理的药代动力学模型。
Clin Pharmacokinet. 2018 Jun;57(6):749-768. doi: 10.1007/s40262-017-0594-5.
7
Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.人细胞色素 P450 2D6 的多态性及其临床意义：第二部分。
Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000.
8
Population pharmacokinetics of ondansetron: a covariate analysis.昂丹司琼的群体药代动力学：一项协变量分析。
Br J Clin Pharmacol. 1998 Aug;46(2):117-25. doi: 10.1046/j.1365-2125.1998.00756.x.
9
Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.昂丹司琼。其药理学综述及新应用中的初步临床研究结果。
Drugs. 1996 Nov;52(5):773-94. doi: 10.2165/00003495-199652050-00010.
10
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.利用体外和体内数据评估代谢性药代动力学相互作用的可能性。
Clin Pharmacokinet. 1997 Mar;32(3):210-58. doi: 10.2165/00003088-199732030-00004.
本文引用的文献
1
The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.肝功能损害患者静脉注射昂丹司琼的药代动力学。
Br J Clin Pharmacol. 1993 Apr;35(4):441-3. doi: 10.1111/j.1365-2125.1993.tb04164.x.
2
The metabolism of ondansetron.
Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S75-7.
3
Pharmacological and anti-emetic properties of ondansetron.昂丹司琼的药理及止吐特性。
Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S15-9.
4
Review of methods and criteria for the evaluation of bioequivalence studies.生物等效性研究评估方法与标准综述
Eur J Clin Pharmacol. 1990;38(1):5-10. doi: 10.1007/BF00314794.
5
Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers.
Clin Pharmacol Ther. 1992 Jan;51(1):51-5. doi: 10.1038/clpt.1992.7.
6
Tropisetron. A review of the clinical experience.
Drugs. 1992;43 Suppl 3:11-22. doi: 10.2165/00003495-199200433-00005.
7
Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.采用气相色谱-火焰离子化和氮选择性检测法测定生物流体中的异喹胍及其4-羟基代谢物。
J Chromatogr. 1977 Mar 11;133(1):161-6. doi: 10.1016/s0021-9673(00)89216-x.
Zotero 插件